174 related articles for article (PubMed ID: 38503865)
1. CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract][Full Text] [Related]
2. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
3. Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Liu M; Fan H; Li T; Sihong L; Qiao S; Bi J
Pathol Res Pract; 2020 Jul; 216(7):152962. PubMed ID: 32534699
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
5. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Zhang W; Zhou L; Di J
Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
[TBL] [Abstract][Full Text] [Related]
9. CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
Yang B; Chen J; Teng Y
J Immunol Res; 2021; 2021():6645885. PubMed ID: 33628849
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CDK12 alterations in a pan-cancer database.
Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
[TBL] [Abstract][Full Text] [Related]
11. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
12. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
13. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
14. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.
Thanindratarn P; Dean DC; Feng W; Wei R; Nelson SD; Hornicek FJ; Duan Z
Eur Spine J; 2020 Dec; 29(12):3214-3228. PubMed ID: 32691223
[TBL] [Abstract][Full Text] [Related]
16. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
17. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
19. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
20. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Choi SH; Kim S; Jones KA
Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
